Why ddPCR Is Becoming The Standard For Gene Therapy Biodistribution, And What That Means For Your CRO

The shift from qPCR to ddPCR in gene therapy biodistribution isn’t a trend — it’s a response to the analytical realities of modern CGT programs. As vector doses become more precise and regulatory expectations more exacting, sponsors need platforms capable of reliably detecting extremely low copy numbers across diverse tissue types. qPCR, while familiar and scalable, struggles in this regime. Its dependence on standard curves, sensitivity to amplification efficiency, and vulnerability to matrix inhibitors create reproducibility and accuracy challenges precisely where data must be most defensible.

ddPCR addresses these limitations structurally. By partitioning samples into thousands of droplets and quantifying absolute copy number, it delivers the precision, sensitivity, and inter‑lab consistency required for IND‑enabling biodistribution packages. This shift carries major implications for CRO selection. Running ddPCR well requires specialized instrumentation, tissue‑specific validation experience, rigorous droplet quality control, and a deep understanding of failure modes that only develops through repetition.

For programs aiming to avoid revalidation delays, regulatory questions, or mid‑development platform transitions, choosing a CRO with ddPCR as a core competency — not an occasional service — can streamline timelines and strengthen the quality of the entire data package.